Purpose: The purpose of this study is to determine if there is a difference in clinical remission rates with different treatment regimens in pediatric inflammatory bowel disease BD patients after anti-TNF failure.
Specific Aims:
- Compare rates of steroid-free, clinical remission at 52 weeks in pediatric ulcerative colitis patients treated with ustekinumab, vedolizumab, or a second anti-TNF-a medication after treatment failure with one anti-TNF-a
- Determine the effect of combination therapy by evaluating rates of steroid-free, clinical remission in pediatric ulcerative colitis patients treated with vedolizumab or ustekinumab with and without an immunomodulator at 52 weeks of treatment.
- Evaluate serious infection rates between patients treated with a second anti-TNF-a medication, vedolizumab, and ustekinumab.
Study Period: August 2020-August 2021
Contact: Kimberly Sutton